From foxglove to diuretics (1785–1960s). The modern story of heart failure (HF) starts with William Withering’s 1785 monograph describing digitalis (foxglove) for “dropsy,” a syndrome we now recognize as HF; digoxin remained a mainstay for symptom control for centuries. PubMe Project GutenbergNew England Journal of Medicine In the mid-20th century, oral thiazide diuretics arrived (chlorothiazide in 1957), followed by loop diuretics (furosemide, FDA-approved 1966), transforming decongestion in HF. PMCJAMA NetworkDrugs.com
The vasodilator and angiotensin-converting enzyme (ACE)-inhibitor era (1980s–early 1990s). Vasodilators were first to show survival benefits: V-HeFT I (1986) found hydralazine–isosorbide dinitrate (H-ISDN) reduced mortality vs placebo; V-HeFT II later showed enalapril outperformed H-ISDN. PubMed2 Minute Medicine Landmark ACE-inhibitor trials then defined disease-modifying therapy: CONSENSUS (1987) in severe HF and SOLVD-Treatment (1991) in ambulatory HF both reduced mortality with enalapril. New England Journal of Medicine+1
Neurohormonal blockade expands (late 1990s–2000s). Beta-blockers became foundational after MERIT-HF (metoprolol CR/XL), CIBIS-II (bisoprolol), and COPERNICUS (carvedilol) each showed mortality benefits in HF with Reduced Ejection Fraction (HFrEF). New England Journal of MedicineThe LancetPubMed Angiotensin receptor blockers (ARBs) provided alternatives/add-on therapy (Val-HeFT; CHARM programs). New England Journal of MedicinePubMed Aldosterone antagonists followed: RALES (spironolactone) reduced death in advanced HFrEF; EPHESUS (eplerenone) after MI with LV dysfunction, and EMPHASIS-HF in milder HFrEF extended the class’s reach. New England Journal of Medicine+2New England Journal of Medicine+2 For self-identified Black patients with HFrEF, A-HeFT (2004) re-established H-ISDN as mortality-reducing add-on therapy. New England Journal of Medicine
Devices and advanced therapies (2000s). Sudden-death prevention and resynchronization reshaped outcomes: MADIT-II showed implantable cardioverter-defibrillator (ICD) improved survival post-MI with low EF; COMPANION and CARE-HF proved cardiac resynchronization therapy (CRT, ± ICD) reduces death/hospitalization in wide-QRS HF. New England Journal of Medicine+2New England Journal of Medicine+2 For end-stage disease, transplantation (pioneered in 1967; later enabled by cyclosporine) and durable LVADs (REMATCH trial; continuous-flow HeartMate II) created viable long-term options. PMCNew England Journal of Medicine+2
The angiotensin receptor blocker and neprilysin inhibitor (ARNI) and sodium-glucose co-transporter 2 (SGLT2) inhibitor era (2014–present). PARADIGM-HF (2014) showed the ARNI sacubitril/valsartan superior to enalapril for CV death or HF hospitalization, ushering in “quadruple therapy.” New England Journal of Medicine SGLT2 inhibitors then proved powerful across the EF spectrum: DAPA-HF (2019) and EMPEROR-Reduced (2020) in HFrEF; EMPEROR-Preserved (2021) and DELIVER (2022) extending benefits to HF with preserved ejection fraction (HFpEF) and HF with mid-range ejection fraction (HFmrEF). New England Journal of Medicine+1The Lancet+1 Additional modern options include vericiguat after recent decompensation (VICTORIA), IV iron for iron deficiency (AFFIRM-AHF; IRONMAN), and the myotrope omecamtiv mecarbil (GALACTIC-HF).
Diagnosis and staging advances. The Framingham criteria (1971) standardized clinical diagnosis and epidemiology. New England Journal of Medicine Discovery of B-type natriuretic peptide (1988) and subsequent trials (e.g., Breathing Not Properly; NEJM BNP study) established BNP/NT-proBNP testing for diagnostic and prognostic use. NatureBlake WachterNew England Journal of Medicine
Current guidelines. Contemporary guidelines (AHA/ACC/HFSA 2022; ESC 2021/2023 update) recommend foundational quadruple therapy for HFrEF, with ARNI/ACEi/ARB + evidence-based β-blocker + mineralocorticoid receptor antagonists (MRA) + SGLT2 inhibitor, device therapy, iron repletion, and advanced therapies as appropriate—and emphasize prevention and staging from “at risk” through advanced HF. Recommendations for HFpEF (LVEF ≥ 50%) are less robust but evolving. AHAA JournalsHeart Failure Society of AmericaOxford Academic+1
Summary. The management of HF has progressed from symptom-relief with digitalis and diuretics to modern evidence-based, disease-modifying strategies. For HFrEF, contemporary guidelines recommend “quadruple therapy” with an ARNI (or ACEi/ARB), an evidence-based β-blocker, a mineralocorticoid receptor antagonist, and an SGLT2 inhibitor, with ICD/CRT devices, iron repletion, and advanced options for select patients; Guideline-directed medical therapy should be initiated or continued during hospitalization and maintained even if EF improves. For HFpEF, effective therapies were long limited to diuretics for congestion, but recent trials support SGLT2 inhibitors and possibly MRAs, ARBs, or ARNI. These strategies, codified in US and European guidelines, reflect the evolution from symptomatic care to comprehensive, outcome-driven management across the HF spectrum.
Source: Revised from ChatGPT